PubMed
Alpha-MSH tripeptide analogs reduce inflammation
Luger et al., 2004
Immune SupportResearch OnlyB
KPV
α-MSH C-terminal tripeptide
KPV is the C-terminal tripeptide (Lys-Pro-Val) of alpha-melanocyte stimulating hormone (α-MSH), retaining its potent anti-inflammatory properties without melanocortin receptor-dependent melanization effects. Research demonstrates significant potential for inflammatory bowel disease (IBD), Crohn's disease, skin inflammatory conditions, and wound healing. Oral formulations show promise for gut-specific delivery. Research only.
Observational report only — live community data. Not medical advice. Does not recommend doses, protocols, or treatments.
- Studies cited
- 7
- Research grade
- B
- Experience
- 99
- Activity
- 49
Overall check-ins
Trackers & reports
Overview
About KPV
KPV is the C-terminal tripeptide (Lys-Pro-Val) of alpha-melanocyte stimulating hormone (α-MSH), retaining its potent anti-inflammatory properties without melanocortin receptor-dependent melanization effects. Research demonstrates significant potential for inflammatory bowel disease (IBD), Crohn's disease, skin inflammatory conditions, and wound healing. Oral formulations show promise for gut-specific delivery. Research only.
- Category
- Immune Support
- Regulatory status
- Research Only
- Also known as
- α-MSH C-terminal tripeptide
- Self-reports
- 54
Community
What 54 users report
54 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 98% · Mixed 2% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Recovery
210
Mood
210
Self-reported dose per injection
Median bucket: 0.2–0.4 mg · Most common: 0.2–0.4 mg
Reports span 0.2–3 mg
0.2–0.4 mg
116
0.4–0.6 mg
89
0.6–1 mg
3
1–2 mg
1
2–3 mg
1
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
How repeat users are trending
Among repeat reporters, 95% said they felt similar to their last entry, 5% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 60 days · Based on 43 repeat reporters
Research
Cited research (6)
Source
PubMed
KPV tripeptide exerts anti-inflammatory effects in intestinal epithelial cells
Brzoska et al., 2010
PubMed
Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease
Kannengiesser et al., 2008
PubMed
alpha-Melanocyte-stimulating hormone, MSH 11-13 KPV and adrenocorticotropic hormone signalling in human keratinocyte cells
Elliott et al., 2004
ClinicalTrials.gov
KPV peptide studies on ClinicalTrials.gov
ClinicalTrials.gov, 2024
PubMed
The neuroimmunomodulatory peptide alpha-MSH
Ichiyama et al., 2000
Tools
Explore more
Explore
More ways to learn about KPV from observational PeptIQ data.
Help
Frequently asked
What do PeptIQ users report about KPV?
This page summarizes 54 anonymized self-reports from PeptIQ users who track KPV, including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.
How do side effects relate to overall experience for KPV?
PeptIQ separates overall check-in ratings (favorable, mixed, or unfavorable) from logged side effects like nausea or fatigue. Users often report benefits and side effects in the same check-in — a high experience score does not mean zero side effects were noted.
What research is cited for KPV?
6 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.
Is KPV safe to use?
This wiki does not assess safety or recommend use. KPV is listed as Research Only. Consult a licensed clinician for personal medical decisions.
What are the purported benefits and uses of KPV?
This wiki summarizes observational community reports and linked citations for KPV. It does not assert therapeutic benefits. See the cited research list on this page and the educational profile for KPV for study-level context — not medical advice.
What is the legal status of KPV?
KPV is listed in PeptIQ as Research Only. Regulatory status varies by jurisdiction and can change. This wiki does not provide legal advice; check current FDA and local rules and talk with a licensed clinician or counsel for personal decisions.
What are the known or theoretical side effects and risks of KPV?
Safety data quality for KPV varies widely by compound and study design. PeptIQ does not establish a risk profile here. Review primary literature, product labeling where applicable, and clinician guidance. Community self-reports are not a substitute for clinical evidence.
What is the current state of research on KPV?
This page links 6 indexed sources for KPV. Evidence maturity differs by application — some peptides have large human programs, others are mostly preclinical. Treat citation counts as literature volume, not proof of efficacy.